GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Geovax Labs Inc (NAS:GOVXW) » Definitions » Forward PE Ratio

Geovax Labs (Geovax Labs) Forward PE Ratio : 0.00 (As of May. 26, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Geovax Labs Forward PE Ratio?

Geovax Labs's Forward PE Ratio for today is 0.00.

Geovax Labs's PE Ratio without NRI for today is 0.00.

Geovax Labs's PE Ratio for today is 0.00.


Geovax Labs Forward PE Ratio Historical Data

The historical data trend for Geovax Labs's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Geovax Labs Forward PE Ratio Chart

Geovax Labs Annual Data
Trend
Forward PE Ratio

Geovax Labs Quarterly Data
Forward PE Ratio

Competitive Comparison of Geovax Labs's Forward PE Ratio

For the Biotechnology subindustry, Geovax Labs's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Geovax Labs's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Geovax Labs's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Geovax Labs's Forward PE Ratio falls into.



Geovax Labs Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Geovax Labs  (NAS:GOVXW) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Geovax Labs Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Geovax Labs's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Geovax Labs (Geovax Labs) Business Description

Traded in Other Exchanges
Address
1900 Lake Park Drive, Suite 380, Smyrna, GA, USA, 30080
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.